Candel Therapeutics Reports Q2 2026 Quarterly Results

What Happened

• On August 13, 2026, Candel Therapeutics, Inc. (CADL) announced its financial results for the quarter ended June 30, 2026. The company furnished a press release announcing the results as Exhibit 99.1 to the Form 8‑K.
• The Form 8‑K states that the furnished information (including Exhibit 99.1) is being provided and is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The report is signed by President and CEO Paul Peter Tak, M.D., Ph.D.

Key Details

• Announcement date: August 13, 2026.
• Reporting period: quarter ended June 30, 2026.
• Disclosure vehicle: press release furnished as Exhibit 99.1 to the Form 8‑K.
• Legal note: information is furnished (not filed) and thus is not subject to Section 18 liability.

Why It Matters

• This 8‑K notifies investors that Candel has publicly released its quarterly results; the press release likely contains the detailed figures investors care about (revenue, net income/loss, cash position, and any operational updates).
• Because the disclosure is furnished rather than filed, it is timely disclosure but carries different legal treatment under the securities laws. Investors should read Exhibit 99.1 (the press release) for the specific financial metrics and any guidance or business updates before making investment decisions.